February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What's the Next Big Question in HIV Treatment?|
|Coverage of IAS 2015: The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention|
|The Day the HIV Treatment Pendulum Stopped Swinging|
|Same-Day Antiretroviral Therapy on Diagnosis: The Future Model for HIV Care|
|New Antiretrovirals, New Formulations and New Strategies for HIV Treatment|
|Long-Term HIV Remission Case Raises More Questions Than Answers|